title: Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine.
authors.affiliation: Hematology Service, Hospital San Pedro, Calle Piqueras 98, 26006, Logroño, La Rioja, Spain, rgmunoz@riojasalud.es.
authors.forename: Ricardo
authors.initials: R
authors.lastname: García-Muñoz
authors.forename: Diana K
authors.initials: DK
authors.lastname: García
authors.forename: Verónica
authors.initials: V
authors.lastname: Roldán-Galiacho
authors.forename: Miriam
authors.initials: M
authors.lastname: Merchante-Andreu
authors.forename: Andrea
authors.initials: A
authors.lastname: Campeny-Najara
authors.forename: Pilar
authors.initials: P
authors.lastname: Rabasa
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D000069461:Bendamustine Hydrochloride; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride